ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) posted its earnings results on Friday. The specialty pharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.42 by $0.38, RTT News reports. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%. The company had revenue of $211.37 million for the quarter, compared to the consensus estimate of $187.18 million. During the same quarter in the prior year, the company earned $1.02 earnings per share. ANI Pharmaceuticals's revenue was up 53.2% on a year-over-year basis.
ANI Pharmaceuticals Price Performance
ANI Pharmaceuticals stock traded up $5.77 during midday trading on Monday, reaching $87.25. 407,745 shares of the stock traded hands, compared to its average volume of 338,943. The stock's fifty day moving average is $65.19 and its 200-day moving average is $63.90. ANI Pharmaceuticals has a 12 month low of $52.50 and a 12 month high of $86.14. The stock has a market cap of $1.89 billion, a P/E ratio of -113.19 and a beta of 0.61. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39.
Wall Street Analyst Weigh In
A number of analysts have commented on the company. Piper Sandler restated an "overweight" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Friday. HC Wainwright restated a "buy" rating and issued a $93.00 price target (up previously from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday. Wall Street Zen cut ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. Truist Financial upped their price target on ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a research report on Monday. Finally, Guggenheim restated a "buy" rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $84.75.
Read Our Latest Stock Report on ANIP
Insider Activity at ANI Pharmaceuticals
In related news, VP Meredith Cook sold 400 shares of the stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $64.88, for a total transaction of $25,952.00. Following the completion of the transaction, the vice president directly owned 78,945 shares of the company's stock, valued at approximately $5,121,951.60. This represents a 0.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Christopher Mutz sold 4,000 shares of the stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total value of $241,800.00. Following the transaction, the insider directly owned 107,317 shares of the company's stock, valued at approximately $6,487,312.65. The trade was a 3.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,681 shares of company stock valued at $345,222. Insiders own 12.70% of the company's stock.
Hedge Funds Weigh In On ANI Pharmaceuticals
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of ANI Pharmaceuticals by 0.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company's stock valued at $3,235,000 after purchasing an additional 423 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $2,706,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of ANI Pharmaceuticals by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company's stock worth $736,000 after acquiring an additional 470 shares during the last quarter. Finally, Advisors Asset Management Inc. bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $28,000. 76.05% of the stock is owned by institutional investors.
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Further Reading

Before you consider ANI Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.
While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.